Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 4, 2026

ASUS Googlebook 14 Now Available for Purchase in the United States

View original at finance.yahoo.com
ASUS Googlebook 14 Now Available for Purchase in the United States ASUS Computer International Designed for Gemini Intelligence, the ASUS Googlebook 14 empowers users to work, create, and collaborate anywhere with an ultraportable design, personalized AI assistance, and access to desktop-class apps Fremont, CA, Oct…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The laptop weighs 2.18 lb and is 0.43 inches thin, with a CNC-machined magnesium-aluminum alloy chassis finished in Dusk Ash and protected by Nano Ceramic Technology.

    60% confidence

  • Every purchase of the Googlebook 14 comes with up to $500 in additional value through a curated bundle of apps and services.

    60% confidence

  • The Googlebook 14 is tested to meet MIL-STD 810H and ASUS Superior Durability standards.

    60% confidence

  • A 70Wh battery provides up to 18 hours of battery life, and an advanced cooling system sustains performance while keeping operation whisper-quiet.

    60% confidence

  • The ASUS Googlebook 14 (CX9406CAA) is now available for purchase in the United States and is the first-ever ASUS laptop designed for Gemini Intelligence.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com